SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc Apr 17, 2023 02:32PM
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association Apr 17, 2023 02:30PM
BeiGene to Present at the Morgan Stanley 20th Annual Global Healthcare Conference Sep 7, 2022 07:27PM
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene Apr 25, 2022 04:09PM
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of Directors Feb 1, 2022 07:00AM


Mar 30, 2021 08:30AM BeiGene Announces New Chief Financial Officer, Julia Wang
Sep 21, 2020 07:00AM Leap Therapeutics and BeiGene Announce First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer
Aug 6, 2020 04:05PM BeiGene Reports Second Quarter 2020 Financial Results
Aug 5, 2020 07:00AM BeiGene Announces Data on Tislelizumab and Pamiparib to Be Presented at the 2020 European Society for Medical Oncology (ESMO) Virtual Congress
Jul 27, 2020 09:16AM BeiGene (BGNE) Announces Priority Review Granted to its NDA of Pamiparib in Ovarian Cancer in China
Jul 27, 2020 09:15AM Priority Review Granted to BeiGene’s New Drug Application of Pamiparib in Ovarian Cancer in China
Jul 20, 2020 06:30AM Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
Jul 17, 2020 09:01AM BeiGene (BGNE) Announces Acceptance of NDA of Pamiparib in Ovarian Cancer in China
Jul 17, 2020 09:00AM BeiGene Announces Acceptance of a New Drug Application of Pamiparib in Ovarian Cancer in China
Jul 15, 2020 05:00PM BeiGene Announces Closing of Approximately $2.08 Billion Registered Direct Offering
Jul 12, 2020 08:00PM BeiGene Announces Pricing of Approximately $2.08 Billion Registered Direct Offering
Jul 2, 2020 07:00AM BeiGene to Host Investor Conference Call and Webcast to Discuss the Company’s Early Development Pipeline and Research
Jul 1, 2020 06:00PM BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Patients with Previously Treated Unresectable Hepatocellular Carcinoma in China
Jul 1, 2020 07:00AM BeiGene Announces Appointment of Angus Grant as Chief Business Executive
Jun 30, 2020 07:30PM BeiGene Begins Commercializing XGEVA® (Denosumab) in China
Jun 22, 2020 09:04AM BeiGene (BGNE) and SpringWorks (SWTX) Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clini
Jun 22, 2020 09:00AM BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial
Jun 19, 2020 12:27AM BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China
Jun 18, 2020 07:36AM BeiGene (BGNE) Announces EMA Acceptance of its MAA for BRUKINSA for Treatment of Patients with Waldenström’s Macroglobulinemia
Jun 18, 2020 07:30AM BeiGene Announces European Medicines Agency Acceptance of its Marketing Authorization Application for BRUKINSA® (Zanubrutinib) for the Treatment of Patients with Waldenström’s Macroglobulinemia
Jun 12, 2020 02:30AM BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress
Jun 5, 2020 07:30AM BeiGene to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
Jun 3, 2020 07:16AM BeiGene (BGNE) Announces Approval of BRUKINSA in China for Patients with R/R CLL or SLL and R/R MCL
Jun 3, 2020 07:15AM BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Ce
May 29, 2020 08:00AM BeiGene Presents Phase 3 Data on Tislelizumab Combined with Chemotherapy for the Treatment of Patients with Advanced Squamous Non-Small Cell Lung Cancer at the 2020 American Society of Clinical Oncolo
May 29, 2020 08:00AM BeiGene Presents Updated Head to Head Results from Phase 3 Trial of Zanubrutinib vs. Ibrutinib in Patients with Waldenström’s Macroglobulinemia at the 2020 American Society of Clinical Oncology (AS
May 26, 2020 04:05PM BeiGene to Host Investor Conference Call and Webcast to Discuss Clinical Study Results Presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program
May 21, 2020 07:07AM BeiGene (BGNE), Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of NDA for BTK Inhibitor BRUKINSA in Israel
May 21, 2020 07:00AM BeiGene and Medison Pharma Announce Exclusive Distribution Agreement and Acceptance of New Drug Application for BTK Inhibitor BRUKINSA™ (zanubrutinib) in Israel
May 20, 2020 07:00AM BeiGene to Present at the Bernstein 36th Annual Strategic Decisions Conference
May 15, 2020 07:00AM BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
May 14, 2020 09:00AM BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress
May 11, 2020 04:05PM BeiGene Reports First Quarter 2020 Financial Results
Apr 29, 2020 05:00PM BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting
Apr 20, 2020 04:15PM BeiGene (BGNE) Announces Acceptance of sNDA for Tislelizumab in Combination with Chemotherapy in First-Line Advanced NSCLC
Apr 20, 2020 04:05PM BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China
Apr 13, 2020 04:07PM BeiGene (BGNE) Announces Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line NSCLC Met Primary Endpoint of PFS at Interim Analysis
Apr 13, 2020 04:05PM BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Sur
Apr 10, 2020 06:00PM China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma